The FDA warns the elderly to avoid this vaccine after mortal complications
Trump, RFK Jr. launch of $ 500 million universal vaccine initiative
News senior medical analyst, Dr. Marc Siegel, analyzes the Trump administration initiative to develop a vaccine to go to multiple viruses and the Murduoch Child Research Institute that studies possible Strep vaccines.
Older adults are noticed who do not receive the Chikungunya vaccine before traveling.
IXCHIQ vaccination, developed by Valneva to prevent Chikungunya virus transmitted by mosquitoes, was approved by the Food and Medicines Administration (FDA) in November 2023 as the first of its kind.
Approval applies to any person over 18 who has the risk of being exposed to the virus.
First vaccine for the Chikungunya virus, a threat of emerging global health, “obtains the approval of the FDA
But the FDA and the Centers for Disease Control and Prevention (CDC) published a security notice on May 9, recommending that adults over 60 years of age pausen the use of the vaccine due to fatal complications.
“The FDA and the CDCs will continue the evaluation of security reports after marketing for Ixchiq,” says the statement.
Older adults are noticed who do not receive the Chikungunya vaccine before traveling. (Istock)
“While Ixchiq’s security for use in individuals of 60 years and older is being evaluated more, the FDA and CDC recommend a pause in the use of the vaccine in this age group. The FDA and the CDC will update to the public when the agencies complete their evaluation of this security problem.”
The notice follows the reports of “serious adverse events”, including neurological and cardiac events in people who received the vaccine.
Click here to get the News application
Two of the 17 events resulted in death due to serious complications. A death was caused by encephalitis or inflammation in the brain, the alert declared.
It was reported that those who experienced adverse effects of the vaccine had between the ages of 62 and 89.
A patient infected with Chikungunya looks from the mosquito network at the Hospital de Clínicas in San Lorenzo, Paraguay, in March 2023. The FDA warned that Ixchiq, which contains a living and weakened version of the virus, can cause symptoms similar to Chikungunya. (Photo AP/Jorge Saenz)
The FDA warned that Ixchiq, which contains a living and weakened version of Chikungunya, can cause symptoms similar to virus.
The typical symptoms of Chikungunya include fever, severe joint pain, headache, muscle pain and an eruption, according to CDC.
Click here to register in our health newsletter
Most people recover within a week, but some may experience pain in the “severe and disabling” joints “for weeks or months.
Chikungunya extends through infected mosquito bite. (Istock)
“This virus is in a similar category that Dengue or Zika and is transported by the same mosquitoes,” said News senior medical analyst, Dr. Marc Siegel, News Digital.
At the time of vaccine approval, the FDA described Chikungunya as a “emerging global health threat”, with at least five million cases reported in the last 15 years.
For more health articles, visit www.Newsnews.com/health
The FDA plans to carry out an “updated benefit risk assessment” for the use of IXCHIQ in those over 60, according to the notice.
Melissa Rudy of News Digital contributed to this report.
Angelica Stabile is a lifestyle reporter for News Digital.